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Abstract: In primary ciliary dyskinesia (PCD) patients, Pseudomonas aeruginosa is a major opportunistic
pathogen, frequently involved in chronic infections of the lower airways. Infections by this
bacterial species correlates with a worsening clinical prognosis and recalcitrance to currently
available therapeutics. The antimicrobial peptide, lin-SB056-1, in combination with the cation
chelator ethylenediaminetetraacetic acid (EDTA), was previously demonstrated to be bactericidal
against P. aeruginosa in an artificial sputum medium. The purpose of this study was to validate
the anti-P. aeruginosa activity of such a combination in PCD sputum and to evaluate the in vitro
anti-virulence effects of EDTA. In combination with EDTA, lin-SB056-1 was able to significantly reduce
the load of endogenous P. aeruginosa ex vivo in the sputum of PCD patients. In addition, EDTA
markedly reduced the production of relevant bacterial virulence factors (e.g., pyocyanin, proteases,
LasA) in vitro by two representative mucoid strains of P. aeruginosa isolated from the sputum of PCD
patients. These results indicate that the lin-SB056-1/EDTA combination may exert a dual antimicrobial
and anti-virulence action against P. aeruginosa, suggesting a therapeutic potential against chronic
airway infections sustained by this bacterium.
Keywords: antimicrobial peptide; EDTA; Pseudomonas aeruginosa; primary ciliary dyskinesia;
virulence factor; anti-virulence; sputum; chronic infection
1. Introduction
Primary ciliary dyskinesia (PCD) is an autosomal recessive disorder characterized by abnormal
ciliary ultrastructure and function leading to impaired mucociliary clearance and recurrent respiratory
infections [1]. Although Haemophilus influenzae is the pathogen most commonly isolated from patients
with PCD until adolescence/early adulthood, in adult PCD patients, P. aeruginosa plays a major
role, especially after the age of 30 [1]. Accordingly, a negative correlation between the abundance of
P. aeruginosa in the airways of these patients and lung function has been reported [2,3]. The pathogenesis
of P. aeruginosa infection is at least partially attributable to its ability to synthesize and secrete a number
of virulence factors (e.g., pyoverdine, pyocyanin, proteases) and to form biofilms, in which bacterial
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cells are embedded in an alginate extracellular matrix [4]. Despite intensive antibiotic therapy, once the
patients are stably colonized by P. aeruginosa, the eradication of the bacterium is rarely achieved [1,5].
Therefore, there is a critical need for novel antimicrobial drugs that can effectively lower P. aeruginosa
load in the challenging environment of PCD lung.
Over the last decades, antimicrobial peptides (AMPs) have been intensively investigated as
potential antibiotics against multidrug-resistant bacteria [6]. Most AMPs are cationic molecules with
an amphipathic structure that selectively target bacterial membranes via electrostatic forces. In contrast
to standard antibiotics, AMPs are generally effective against both quiescent and actively growing
bacteria, display rapid killing kinetics, and demonstrate low propensity to select resistant mutants
in vitro [7,8]. On the other hand, AMPs may display a reduction in their antibacterial potency in the
presence of complex biological fluids such as sputum, plasma, or saliva due to the high concentration
of salt found in these fluids and/or the presence of anionic proteins and host or bacterial proteases that
may neutralize their activity [9,10].
As observed in cystic fibrosis (CF) lungs, the biofilm mode of growth of bacteria together
with the lung mucus viscosity reduces the effectiveness of conventional antibiotic therapy in PCD
patients [11]. Thus, the usage of adjuvants has been proposed to improve the diffusion of antimicrobials
through the mucus and the biofilm matrix and facilitate the targeting of bacterial cells [12]. Previous
studies have shown that the divalent cation chelator ethylenediaminetetraacetic acid (EDTA) can
destabilize the biofilm structure by interfering with the ionic attractive forces among the biofilm
matrix components [13,14]. EDTA is prescribed in a number of clinical conditions demonstrating high
tolerability (up to 2 g once a week, intravenously injected) and efficacy [15]. Recently, we demonstrated
that the optimized semi-synthetic antimicrobial peptide lin-SB056-1 in combination with EDTA is
able to exert a synergistic bactericidal effect against P. aeruginosa in an artificial sputum medium
resembling CF sputum [16]. Similarities and differences between CF and PDC sputum have been
reported. For instance, while both diseases seem to be associated with a similar degree of airways
neutrophilia, the concentration of interleukin-8 in sputum is higher in PCD than in CF patients, while
neutrophil elastase activity is lower in PCD compared with CF [17]. In order to evaluate the therapeutic
potential of the lin-SB056-1/EDTA combination in PCD, in this study, we evaluated its bactericidal
activity ex vivo, against endogenous P. aeruginosa in the sputum from PCD patients. Importantly,
the ex vivo sputum mimics, with good approximation, the lung environment, as it contains both
host and bacterial components, including bronchial mucus contaminated by saliva, serum proteins,
inflammatory mediators, desquamated epithelial cells, and pathogenic bacteria, as well as bacteria
from the normal flora [18].
Previous reports have demonstrated the involvement of different cations (i.e., calcium, magnesium,
and zinc) either in the regulation of gene expression or in the production and processing of virulence
factors in P. aeruginosa [19,20]. Thus, herein, we also evaluated the ability of EDTA to reduce the
production of relevant virulence factors of P. aeruginosa (e.g., pyoverdin, pyocyanin, proteases, biofilm
production). Overall, the results obtained demonstrated that the lin-SB056-1/EDTA combination is able
to significantly reduce P. aeruginosa load ex vivo and that EDTA is highly active in suppressing the
production of relevant bacterial virulence factors, suggesting a dual antibacterial and anti-virulence
potential of the combination.
2. Results
2.1. Killing Activity of lin-SB056-1 in Combination with Ethylenediaminetetraacetic Acid (EDTA) against
Endogenous P. aeruginosa
P. aeruginosa strains were isolated from the sputum of six PCD patients known to be chronically
infected with the bacterium. All the strains displayed a mucoid phenotype and different antibiotic
susceptibility profiles (Supplementary Table S1).
Diluted sputum (5-fold) from each patient was incubated for 1.5 h with the peptide at 25 µg/mL,
alone or in combination with EDTA (0.625 or 1.25 mM), and the colony forming unit (CFU) number
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of P. aeruginosa surviving the treatment was detected. During the incubation time, endogenous
P. aeruginosa did not grow in PCD sputum. While the peptide and EDTA were almost inactive
when used alone, their combination exerted a significant synergistic killing effect against endogenous
P. aeruginosa, although with different efficacy depending on the sputum sample (Figure 1). When
compared to the corresponding controls, the reduction in CFU number caused by the combination
ranged from approximately 0.3 Log-units (50% reduction, grey dot) to 3 Log-units (99.9% reduction,
blue triangle) (Figure 1).
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Figure 1. Antibacterial activity of peptide lin-SB056-1, ethylenediaminetetraacetic acid (EDTA), and both
in combination against endogenous P. aeruginosa in primary ciliary dyskinesia (PCD) sputum. The effect
of lin-SB056-1 and/or EDTA after 1.5 h of incubation in six diluted (1:5) sputum samples was assessed
against endogenous P. aeruginosa strains (PaM1 to PaM6) by colony forming unit (CFU) counting.
Lin-SB056-1 was tested at 25 µg/mL in combination with 0.625 mM EDTA against PaM1 and PaM5
strains (triangles), and with 1.25 mM EDTA against PaM2, PaM3, PaM4, and PaM6 strains (dots).
Control (CTRL): bacteria incubated in diluted sputum only. Individual sputum samples are identified
with different colors. Results represent the mean of 6 sputa done in duplicate. Error bars indicate the
standard error of the mean. ** p < 0.01, *** p < 0.001 (one-way analysis of variance (ANOVA) followed
by the Tukey–Kramer post-hoc test).
2.2. Effects of EDTA and lin-SB056-1 on Virulence Factors’ Production by P. aeruginosa PaM1 and PaM5
Preliminary experiments indicated that PaM1and PaM5 strains are able to produce high levels of
most of the virulenc factor a alyze ; erefore, these strains were selected to eval ate the effect of
sub-inhibitory concentrations of EDTA on virulence factor ’ production. To this aim, we first evaluated
the susceptibility of PaM1 nd PaM5 strains to EDTA i liquid medium, in terms of minimu inhibitory
concentra ion (MIC). A concentr tion of 1.25 mM EDTA was able to inhibit visible bacterial growth
(MIC), while the concentrations f 0.075 and 0.15 mM were sub-inhibitory and therefore, were selected
for the subsequent experiments.
Pyocyanin is a greenish pigm nt secreted by P. aerugi o a that enhances the inflammatory response
and causes tissue damage in the hos [21]. As shown in Figure 2a, EDTA at the concentrations of
0.075 and 0.15 mM, highly inhibited pyocyanin production by the PaM1 strain at 72 h (by 62% and
70%, respectively) as compared to the untreated cells. Regarding the PaM5 strain, which was a low
pyocyanin pro ucer (Figure 2b), EDTA at both concentrations caused a reduction of approxim tely
40% in the production of such pigment, although the difference did not each tatistical significance
compared to the untreated cells.
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P. aeruginosa produces and secretes a number of proteases, such as LasA, elastase B (LasB), protease
IV, and alkaline protease, which are considered important virulence factors as they damage host tissues
and interfere with host antibacterial defense mechanisms [22]. The total proteolytic activity of PaM1
was completely abolished in the presence of either 0.075 or 0.15 mM EDTA (Figure 2a). Similarly,
EDTA significantly reduced the proteolytic activity of the PaM5 strain but only at the concentration of
0.15 mM (Figure 2b).
LasA is a zinc-dependent metalloprotease secreted by P. aeruginosa. It exhibits a staphylolytic
activity, enhances the elastolytic activity of LasB in vivo, and induces shedding of syndecans, a family
of cell surface heparan sulfate proteoglycans, from host cell surfaces [23]. LasA activity of both the
PaM1 and PaM5 strains was significantly inhibited in the presence of 0.075 and 0.15 mM EDTA,
with a reduction of approximately 70% and 80%, as compared to the untreated control, respectively
(Figure 2a,b). Further experiments were undertaken in order to evaluate whether the reduction of
LasA activity was ascribable to the inhibition of protease synthesis or, rather, to the inhibition of the
enzyme activity due to zinc chelation by EDTA (Figure S1). To this aim, the assessment of the PaM1
staphylolytic activity was performed in the presence of exogenously added zinc (0.1 mM ZnSO4).
When ZnSO4 was added directly in the enzyme assay, at the end of the incubation period (72 h), no
significant increase in LasA activity was observed, suggesting that the low levels of LasA activity
detected in the presence of EDTA were likely due to inhibition of protein synthesis and not to the
chelation of the enzyme cofactor. In contrast, when ZnSO4 was added at the beginning of the incubation
of PaM1 with EDTA, LasA activity was restored (Supplementary Figure S1), indicating that the excess
of zinc could overcome the inhibitory effect of EDTA. Overall, these data suggest that EDTA may act by
interfering with the expression/procession of LasA protease by PaM1 strain rather than by sequestering
the zinc cofactor.
Pyoverdin is a chelator involved in iron binding and cellular uptake in a low-iron environment [24].
EDTA at both concentrations tested did not reduce the level of pyoverdin in culture supernatants of
both P. aeruginosa strains (Figure 2a,b).
Studies on mucoid P. aeruginosa isolates have shown that alginate plays a critical role in biofilm
establishment and persistence by protecting bacteria against antibiotics and phagocytosis [25,26].
Although EDTA did not inhibit the production of alginate in culture supernatants of both strains
(Figure 2a,b), it was able to significantly reduce the viscosity of PaM1 culture supernatants at both
concentrations tested (Figure 2a).
Finally, EDTA was tested for its antibiofilm activity against the PaM1 strain. A reduction of
40% and 57% in PaM1 biofilm formation was observed in the presence of 0.075 and 0.15 mM EDTA,
respectively (Figure 2a).
The impact of lin-SB056-1 on the production of virulence factors by PaM1 and PaM5 strains was
also evaluated. As reported in Table S2, the peptide at sub-inhibiting concentrations did not reduce the
production of any of the virulence factors analyzed for both bacterial strains tested.
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Figure 2. Effects of EDTA on virulence factor production by (a) PaM1 and (b) PaM5 strains. PaM1
and PaM5 cultures were incubated at 37 ◦C in the presence or absence of EDTA for 72 h. Following
incubation, OD600 was measured prior the quantification of the virulence factors in culture supernatants
(see the Materials and Methods Section for details). Values obtained were normalized by multiplying
them by the ratio between OD600 of the control/OD600 of the corresponding EDTA-treated samples and
reported as ean +/- SEM of three independent experiments. CTRL: bacteria incubated without EDTA;
* p < 0.05, ** p < 0.01 (one-way ANOVA followed by the Tukey–Kramer post-hoc test).
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3. Discussion
Similar to CF patients, eradication of chronic P. aeruginosa infection in PCD lungs is hardly
obtained, and the reduction of bacterial density during chronic colonization or exacerbations is often
the aim of the antimicrobial therapy [3]. In previous studies, we have shown that the combination of
lin-SB056-1/EDTA possesses antimicrobial activity against P. aeruginosa in artificial sputum medium
and prevents P. aeruginosa biofilm formation in an in vivo-like three-dimensional (3D) lung epithelial
cell model [16,27]. Despite resembling the airway mucus, artificial sputum media normally behave
like Newtonian fluids lacking many of the intramolecular interactions and covalent cross-links that
give respiratory secretions their viscoelastic characteristic [28]. Furthermore, the genotype and
physiological state of P. aeruginosa cells found in vivo may significantly differ from those of bacteria
grown in laboratory media [29]. Hence, in this study, we sought to validate the anti-pseudomonal
activity of the lin-SB056-1/EDTA combination in conditions more closely resembling the environment
found in vivo. To this aim efficacy of the combination was tested ex vivo, against endogenous
P. aeruginosa in the sputum of PCD patients. Differently from artificial sputum medium, patients’
sputum contains host/bacterial components such as cell-derived factors, normal flora, inflammatory
mediators, proteases, or peptidases that may exert an additional inhibitory effect on the peptide’s
activity. Nevertheless, herein, we showed that the combination of lin-SB056-1 and EDTA at sub-active
and non-cytotoxic concentrations [16,27] determined a significant reduction in P. aeruginosa load
in sputa of PCD chronically infected patients, despite certain differences in the level of reduction
among different sputum samples being observed. Such differences are not surprising considering that
inter-patient variables (e.g., clinical stage and severity of lung infection, bacterial load, sputum sample
composition, and consistency) were not standardized in our experiments, in the attempt to mimic
conditions found during the actual antimicrobial therapy. The mechanisms of the synergistic effect
of EDTA on the peptide’s activity might be multiple. Due to the chelation of divalent cations from
their binding sites in lipopolysaccharide (LPS), EDTA may destabilize the bacterial outer membrane,
thus increasing the permeability to lin-SB056-1 molecules and their interaction with the bacterial
membranes. In addition, at least part of the synergistic effect observed in sputum could be ascribed to
the ability of EDTA to reduce sputum viscosity, thus favoring peptide diffusion [16]. Finally, EDTA
could also neutralize the inhibitory effect of sputum on the peptide’s activity, sequestering cations that
may interfere with the electrostatic interactions of the peptide with bacterial surface [9,10]. The possible
use of EDTA in the treatment of pulmonary infections and its safety as an adjuvant has been highlighted
in previous in vivo studies [30,31]. For instance, Liu and coworkers demonstrated, in the guinea pig
model, that EDTA (30 mg/kg intraperitoneally injected) plus ciprofloxacin (4 µg/mL administered by
inhalation) significantly reduced the P. aeruginosa CFU number per gram of lung tissue as compared to
the single treatment groups [31].
Interestingly, the results obtained in this study clearly demonstrated that EDTA could not only
favor the activity of lin-SB056-1 in ex vivo conditions, but could also reduce in vitro, at sub-inhibitory
concentrations, the production of several P. aeruginosa virulence factors (i.e., pyocyanin, total protease
and LasA), which are known to play a crucial role in the pathogenesis of P. aeruginosa infections.
The action of EDTA as an anti-virulence molecule could be ascribed to its capacity of binding divalent
cations, many of which are critical for the expression/processing of virulence factors of P. aeruginosa.
In particular, the reduction of pyocyanin observed in the presence of EDTA is in line with previous
reports demonstrating a positive correlation between calcium levels and the expression of proteins
involved in the pathway of pyocyanin biosynthesis [32]. Analogously, the reduction of proteases
by EDTA is in agreement with previous observations reporting that zinc ions are important for the
efficient production and processing of different proteases, such as LasA, LasB, and protease IV [19,33].
On the contrary, EDTA did not inhibit pyoverdin production, in agreement with the observation
that neither calcium nor magnesium enhances pyoverdin production [34,35]. Interestingly, although
EDTA did not inhibit alginate production, it was able to markedly reduce the viscosity of culture
supernatants of the PaM1 strain. It can be hypothesized that this effect may be due to the sequestration
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of calcium ions that are crucial for alginate cross-linking [36]. A similar mechanism may be involved
in the ability of EDTA to reduce the formation of PaM1 biofilm, confirming previous observations
in which EDTA significantly reduced biofilm formation by a mucoid strain of P. aeruginosa either
in vitro or in a guinea-pig model of lung infection [31]. Overall, the ability of EDTA to reduce the
accumulation and/or activity of important virulence factors might contribute to limit the pathogenicity
of P. aeruginosa.
In conclusion, in the present study, we demonstrated that the lin-SB056-1/EDTA combination is
able to significantly reduce P. aeruginosa load in PCD sputum, and that EDTA decreases the production
of relevant virulence factors of mucoid P. aeruginosa in vitro. Such results suggest a dual antimicrobial
and anti-virulence effect of the lin-SB056-1/EDTA combination and highlight the possible use of EDTA
as an adjuvant in the treatment of chronic P. aeruginosa lung infections.
4. Materials and Methods
4.1. Sputum Collection and Treatment
The sputum samples were collected by spontaneous expectoration from six PCD patients
following informed consent. The study was conducted in accordance with the Declaration of Helsinki,
and the protocol was approved by the Ethics Committee of Pisa (Protocol number 62532, 11.06.2016).
PCD patients included in this study (median age: 34 years) were chronically infected by P. aeruginosa
and characterized by frequent relapses of infection. A volume of 0.5–1 mL of sputum was collected
from each patient after interruption (at least 14 days) of the antibiotic therapy regimen. For easier
handling of the samples, the dense and sticky sputa were diluted five-fold in sodium phosphate buffer
10 mM, pH 7.4 (SPB). Samples were plated on cetrimide (Sigma Aldrich, Saint Louis, MO, USA) and
MacConkey (Oxoid Basingstoke, Hampshire, UK agar to confirm the presence of P. aeruginosa and
assess the mucoid phenotype of the colonies, respectively.
4.2. Peptide and EDTA Solutions
Lin-SB056-1 peptide (KWKIRVRLSA-NH2) was purchased from Peptide Protein Research, Ltd.
(Fareham, UK) with a purity of 98%. EDTA (disodium salt) was obtained from Sigma-Aldrich. A stock
solution of disodium-EDTA (0.5 M) was prepared in milli-Q water by adjusting the pH to 8.0 with
NaOH (Sigma-Aldrich). The stock solution was then diluted in milli-Q water to obtain a working
solution of 50 mM that was sterilized and stored at 4 ◦C.
4.3. Susceptibility Testing
Identification and susceptibility testing of P. aeruginosa strains isolated from sputum samples
(PaM1, PaM2, PaM3, PaM4, PAM5, PaM6) were performed by MALDI-TOF (Bruker Daltonics, Bremen,
Germany) and VITEK 2 automatic instruments (BioMerieux, Lyon, France), respectively (Table S1).
Determination of minimum inhibitory concentration (MIC) of EDTA towards PaM1 and PaM5 strains
was performed according to the standard microdilution method in Muller–Hinton broth (Oxoid) [37].
The MIC was defined as the lowest concentration of EDTA that completely inhibited visible growth of
bacteria after 24 h of incubation.
4.4. Bactericidal Assay in Patients’ Sputum
An aliquot of each PCD sputum was serially diluted and plated on selective cetrimide agar,
to assess the CFU number of endogenous P. aeruginosa at time 0. After that, a volume of 90 µL of
diluted (1:5) sputum of each patient was incubated with sub-bactericidal concentrations of peptide and
EDTA, used alone or in combination, for 1.5 h at 37 ◦C. Following incubation, samples were serially
diluted and plated on selective cetrimide agar for assessing the P. aeruginosa CFU number.
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4.5. Assays for Evaluation of Virulence Factors in Culture Supernatants
Colonies of mucoid strains PaM1 and PaM5 grown on MacConkey agar were suspended in Luria
Bertani (LB) broth (Sigma-Aldrich) to obtain an OD600 of 0.1. Cultures were incubated in the presence
or in the absence of EDTA (0.075 or 0.15 mM) in static conditions at 37 ◦C for 72 h. Following incubation,
the OD600 of the cultures was determined to account for bacterial density. After that, cultures were
centrifuged at 10,000× g for 20 min at room temperature and culture supernatants were used for the
quantification of virulence factors. The same protocol was followed to evaluate the eventual effects of
linSB056-1 on the production of virulence factors. To this aim, the peptide was added to PaM1 and
PaM5 cultures at the concentration of 6.25 µg/mL and 12.5 µg/mL that were sub-inhibitory for both
bacterial strains.
Pyocyanin was extracted from cell-free supernatants with subsequent exposure to chloroform and
0.2 N hydrochloric acid (Sigma-Aldrich) and quantified at OD520 nm, as previously described [38].
Total proteolytic activity was determined using a modified skim milk assay [39]. Briefly, culture
supernatants of PaM1 and PaM5 strains (0.5 mL) were incubated with 0.5 mL skim milk (Sigma-Aldrich)
(1.25%) at 37 ◦C for 30 min and turbidity was measured at OD600 nm. The decrement in turbidity due
to proteolytic activity was expressed as ∆A/min/mL.
Secreted LasA of P. aeruginosa has a staphylolytic activity, i.e., it causes a decrement in the OD600
of a culture of Staphylococcus aureus. LasA activity was assessed by evaluating the ability of cell-free
supernatants from P. aeruginosa exposed or not exposed to EDTA to lyse boiled cells (intact) of S. aureus
American Type Culture Collection (ATCC) 33591 and expressed as ∆A/min/mL [40]. Due to the role of
zinc as a cofactor of LasA, in some experiments, the staphylolytic activity in the presence of EDTA was
evaluated by adding 0.1 mM ZnSO4 (Sigma-Aldrich) to the enzyme assay.
Pyoverdin was quantified by measuring the OD400 of cell-free supernatants [41].
The quantification of alginate was performed by carbazole-borate assay according to Heidari et
al. [42]. Shear viscosity of culture supernatants was assessed by rheometric measurement at 25 ◦C,
applying a shear stress of 1 Pa/s on 150 µl of supernatant using a gap between the rheometer plates of
52 µm (Rheometer Scientific RM500, Reologica Instruments AB, Lund, Sweden).
The value obtained for each virulence factor was multiplied by the ratio OD600 of the control/OD600
of the sample, to normalize for small differences in the culture densities between the controls and the
EDTA-exposed samples after 72 h of incubation.
4.6. Biofilm Inhibition Assay
P. aeruginosa PaM1 grown in tryptone soy broth (TSB) for 48 h at 37 ◦C was diluted 1:20 in TSB
supplemented with 0.25 mM CaCl2. Bacterial suspensions were inoculated into flat-bottom polystyrene
96-well microplates (Corning Costar, Lowell, MA, USA) in the absence (negative control) or in the
presence of EDTA at sub-inhibiting concentrations (0.075 and 0.15 mM). Microplates were incubated
statically at 37 ◦C for 48 h and biofilm biomass was estimated by crystal violet (CV) (Sigma-Aldrich)
staining assay, as previously described [43].
4.7. Statistical Analysis
Data reported in Figure 1 represent the mean of 6 experiments done in duplicate. Figure 2 and
Supplementary Figure S1 depict the data obtained from three independent experiments, while Table S2
reports the mean of two independent experiments. Differences between mean values of groups were
evaluated by one-way analysis of variance (ANOVA) followed by the Tukey–Kramer post-hoc test.
A p-value < 0.05 was considered statistically significant. Data analysis was performed with GraphPad
In Stat (GraphPad Software, La Jolla, CA, USA).
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Table S1: Patients’ information, colony phenotype, and resistance profile of P. aeruginosa strains isolated from PDC
sputum; Table S2: Effects of lin-SB056-1 on the production of virulence factors by PaM1 and PaM5 strains; Figure
S1: Effect of exogenously added Zinc on LasA staphylolytic activity of PaM1 strain in the presence of EDTA.
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ATCC American Type Culture Collection
AMPs Antimicrobial peptides
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